RxDoctor Payments Data

Eli Hendel, MD

Pulmonary Disease · Glendale, CANPI 1871552661

Payments from drug & device makers

$3,834in general payments, 2019–2025

Across 119 payments — averaging $32.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Boehringer Ingelheim$506
  • Actelion Pharmaceuticals US, Inc.$353
  • AstraZeneca$304
  • Jazz Pharmaceuticals Inc.$282
  • Novartis$145
  • plus $739 from 16 others

What the payments were for

  • Consulting fees$190%
  • Food & beverage$3,80299%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,834 in reported general payments places this provider in the 60th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$7,352
Medicare patients
30
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate28$33,162
Breo ElliptaFluticasone/Vilanterol53$22,504
EliquisApixaban19$18,722
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$8,924
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,923
Spiriva RespimatTiotropium Bromide12$8,522
Fluticasone-VilanterolFluticasone/Vilanterol11$4,585
Losartan Potassium107$1,250
Atorvastatin Calcium67$721
Calcitonin-SalmonCalcitonin,salmon,synthetic13$663
Metformin Hcl41$480
Metoprolol Succinate42$403
Rosuvastatin Calcium28$383
Levothyroxine Sodium31$351
Amlodipine Besylate83$311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta$1,505$40,35185 claims
MerckJanuvia$70$33,16228 claims
PfizerEliquis$19$18,72219 claims
Boehringer IngelheimSpiriva Respimat$506$8,52212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →